AM-Pharma appoints new chief executive
pharmafile | September 13, 2011 | Appointment | Manufacturing and Production, Research and Development | appointment, manufacturing and production, research and development
Dutch biopharmaceutical company AM-Pharma has appointed Erik van den Berg as its new chief executive.
He was previously VP business development at the company, which focuses on the preclinical and clinical development of alkaline phosphatase (AP) for the treatment of severe inflammatory diseases.
Erik takes over from Bart Wuurman who AM-Pharma said has left after four years at the helm to take on a new challenge in his career.
AM-Pharma’s chairman Eric Claassen said: “Bart has made a distinctive contribution to the development of AM-Pharma and I would like to thank him for his efforts in turning AM-Pharma into a focused organisation, and for his role in preparing a new round of upcoming financing for the company.”
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …






